<li>acarbose<p>amitriptyline increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>amobarbital<p>amobarbital, amitriptyline. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>armodafinil<p>armodafinil will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>artemether/lumefantrine<p>artemether/lumefantrine will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>atropine<p>amitriptyline increases levels of atropine by unknown mechanism. Minor/Significance Unknown.</p></li><li>atropine iv/im<p>amitriptyline increases levels of atropine iv/im by unknown mechanism. Minor/Significance Unknown.</p></li><li>bazedoxifene/conjugated estrogens<p>bazedoxifene/conjugated estrogens, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>bortezomib<p>bortezomib will increase the level or effect of amitriptyline by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>bosentan<p>bosentan will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>brimonidine<p>amitriptyline decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>budesonide<p>budesonide will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>butabarbital<p>butabarbital, amitriptyline. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>butalbital<p>butalbital, amitriptyline. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>carbamazepine<p>carbamazepine decreases levels of amitriptyline by increasing metabolism. Minor/Significance Unknown.</p></li><li>chlorpromazine<p>amitriptyline, chlorpromazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.<span><br><br></span>amitriptyline, chlorpromazine.
Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>chlorpropamide<p>amitriptyline increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>clobetasone<p>clobetasone will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>conjugated estrogens<p>conjugated estrogens, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>conjugated estrogens, vaginal<p>conjugated estrogens, vaginal, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>cortisone<p>cortisone will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>desflurane<p>desflurane, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.</p></li><li>dexamethasone<p>dexamethasone will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>dexmethylphenidate<p>dexmethylphenidate increases effects of amitriptyline by decreasing metabolism. Minor/Significance Unknown.</p></li><li>dhea, herbal<p>dhea, herbal will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>diltiazem<p>diltiazem increases levels of amitriptyline by decreasing metabolism. Minor/Significance Unknown.</p></li><li>enflurane<p>enflurane, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.</p></li><li>eslicarbazepine acetate<p>eslicarbazepine acetate will increase the level or effect of amitriptyline by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.<span><br><br></span>eslicarbazepine acetate will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>estradiol<p>estradiol, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>estrogens conjugated synthetic<p>estrogens conjugated synthetic, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>estrogens esterified<p>estrogens esterified, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens may inhibit hepatic metabolism of tricyclic antidepressants. However, interactions are not common.</p></li><li>estropipate<p>estropipate, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>ethanol<p>ethanol, amitriptyline.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive impairment of motor skills.</p></li><li>ethinylestradiol<p>ethinylestradiol, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>etomidate<p>etomidate, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.</p></li><li>etravirine<p>etravirine will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>eucalyptus<p>eucalyptus will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.<span><br><br></span>amitriptyline and eucalyptus both increase  sedation. Minor/Significance Unknown.</p></li><li>felodipine<p>felodipine will increase the level or effect of amitriptyline by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>fludrocortisone<p>fludrocortisone will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>fluphenazine<p>amitriptyline, fluphenazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.<span><br><br></span>amitriptyline, fluphenazine.
Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>glimepiride<p>amitriptyline increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>glipizide<p>amitriptyline increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>gliquidone<p>amitriptyline increases effects of gliquidone by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>glyburide<p>amitriptyline increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>griseofulvin<p>griseofulvin will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>hexobarbital<p>hexobarbital will decrease the level or effect of amitriptyline by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.<span><br><br></span>hexobarbital will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.<span><br><br></span>hexobarbital, amitriptyline. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>hydrocortisone<p>hydrocortisone will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>hydroxyprogesterone caproate<p>hydroxyprogesterone caproate, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>insulin aspart<p>amitriptyline increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>insulin detemir<p>amitriptyline increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>insulin glargine<p>amitriptyline increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>insulin glulisine<p>amitriptyline increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>insulin lispro<p>amitriptyline increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>insulin nph<p>amitriptyline increases effects of insulin nph by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>insulin regular human<p>amitriptyline increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>isoniazid<p>isoniazid will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>isoproterenol<p>isoproterenol, amitriptyline. Mechanism: unknown. Minor/Significance Unknown. Risk of cardiac arrhythmias.</p></li><li>itraconazole<p>itraconazole will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>ketamine<p>ketamine, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.</p></li><li>lapatinib<p>lapatinib will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>lithium<p>lithium, amitriptyline. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of neurotoxicity in geriatric pts.  Multiple mechanisms involved.</p></li><li>lumefantrine<p>lumefantrine will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>marijuana<p>marijuana will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>mephobarbital<p>mephobarbital, amitriptyline. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>mestranol<p>mestranol, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>metformin<p>amitriptyline increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>methylphenidate<p>methylphenidate increases effects of amitriptyline by decreasing metabolism. Minor/Significance Unknown.</p></li><li>methylprednisolone<p>methylprednisolone will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>metronidazole<p>metronidazole will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>metyrapone<p>amitriptyline decreases effects of metyrapone by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>mibefradil<p>mibefradil will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>miconazole vaginal<p>miconazole vaginal will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>miglitol<p>amitriptyline increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>modafinil<p>modafinil will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>nateglinide<p>amitriptyline increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>nevirapine<p>nevirapine will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>nifedipine<p>nifedipine will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>nilotinib<p>nilotinib will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>oxcarbazepine<p>oxcarbazepine will increase the level or effect of amitriptyline by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.<span><br><br></span>oxcarbazepine will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>oxiconazole<p>oxiconazole will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>panax ginseng<p>panax ginseng increases effects of amitriptyline by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>parecoxib<p>parecoxib will increase the level or effect of amitriptyline by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>pentobarbital<p>pentobarbital, amitriptyline. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>perphenazine<p>amitriptyline, perphenazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.<span><br><br></span>amitriptyline, perphenazine.
Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>phenobarbital<p>phenobarbital, amitriptyline. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>pioglitazone<p>amitriptyline increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>pleurisy root<p>pleurisy root decreases effects of amitriptyline by unspecified interaction mechanism. Minor/Significance Unknown. Theoretical interaction.</p></li><li>posaconazole<p>posaconazole will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>prednisolone<p>prednisolone will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>prednisone<p>prednisone will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>primidone<p>primidone, amitriptyline. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>prochlorperazine<p>amitriptyline, prochlorperazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.<span><br><br></span>amitriptyline, prochlorperazine.
Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>progesterone micronized<p>progesterone micronized, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>promazine<p>amitriptyline, promazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.<span><br><br></span>amitriptyline, promazine.
Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>promethazine<p>amitriptyline, promethazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.<span><br><br></span>amitriptyline, promethazine.
Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>propofol<p>propofol, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.</p></li><li>quinupristin/dalfopristin<p>quinupristin/dalfopristin will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>repaglinide<p>amitriptyline increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>rosiglitazone<p>amitriptyline increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>rufinamide<p>rufinamide will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>sage<p>amitriptyline and sage both increase  sedation. Minor/Significance Unknown.</p></li><li>saxagliptin<p>amitriptyline increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>secobarbital<p>secobarbital, amitriptyline. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>sevoflurane<p>sevoflurane, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.</p></li><li>sitagliptin<p>amitriptyline increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>sitaxentan<p>sitaxentan will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>sulfamethoxazole<p>sulfamethoxazole decreases levels of amitriptyline by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>telithromycin<p>telithromycin will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>thioridazine<p>amitriptyline, thioridazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.<span><br><br></span>amitriptyline, thioridazine.
Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>tolazamide<p>amitriptyline increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>tolbutamide<p>amitriptyline increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>topiramate<p>topiramate will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>triamcinolone<p>triamcinolone will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>trifluoperazine<p>amitriptyline, trifluoperazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.<span><br><br></span>amitriptyline, trifluoperazine.
Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>troglitazone<p>troglitazone will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.<span><br><br></span>amitriptyline increases effects of troglitazone by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>troleandomycin<p>troleandomycin will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>vasopressin<p>amitriptyline increases effects of vasopressin by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>verapamil<p>verapamil will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.<span><br><br></span>verapamil increases levels of amitriptyline by decreasing metabolism. Minor/Significance Unknown.</p></li><li>vildagliptin<p>amitriptyline increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>voriconazole<p>voriconazole will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>zafirlukast<p>zafirlukast will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>zolpidem<p>zolpidem, amitriptyline.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.</p></li>